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Background: The European Academy of Allergy and Clinical Immunology is in the process of developing its
Guideline for Food Allergy and Anaphylaxis, and this systematic review is one of seven inter-linked evidence
syntheses that are being undertaken in order to provide a state-of-the-art synopsis of the current evidence base in
relation to epidemiology, prevention, diagnosis and clinical management and impact on quality of life, which will
be used to inform clinical recommendations.
The aims of this systematic review will be to understand and describe the epidemiology of anaphylaxis, i.e.
frequency, risk factors and outcomes of anaphylaxis, and describe how these characteristics vary by person, place
and time.
Methods: A highly sensitive search strategy has been designed to retrieve all articles combining the concepts of
anaphylaxis and epidemiology from electronic bibliographic databases.
Discussion: This review will aim to provide some estimates of the incidence and prevalence of anaphylaxis in
Europe. The occurrence of anaphylaxis can have a profound effect on the quality of life of the sufferer and their
family. Estimates of disease frequency will help us to ascertain the burden of anaphylaxis and provide useful
comparators for management strategies.
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Anaphylaxis is a ‘severe, life-threatening generalised or
systemic hypersensitivity reaction’ [1,2]. Several working
definitions of anaphylaxis have been formulated to aid
clinical diagnosis and management [3-6]. The most well-
known of these is the consensus clinical definition pro-
posed by Sampson et al., which involved representatives
of a number of international allergy organisations, in-
cluding the European Academy of Allergy and Clinical
Immunology (EAACI) [7].
Whilst useful clinically, definitions in which the pre-
sumption of exposure to a known trigger substantially
increase the likelihood of making the diagnosis are of
limited value for epidemiological investigations. Hence,* Correspondence: aziz.sheikh@ed.ac.uk
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reproduction in any medium, provided the orcurrent estimates of the epidemiology of anaphylaxis will
be subject to uncertainty depending on the case defin-
ition used [8]. Reliably establishing the epidemiology of
anaphylaxis is further complicated by the fact that it is a
relatively uncommon condition, which is acute in onset
and transient, rendering it difficult to mount prospective
investigations [9]. Investigators may therefore need to
use less than ideal study designs, which further results in
the possibility of generating biased estimates.
Notwithstanding these inherent challenges, there is a
need to improve our understanding of the epidemiology
of anaphylaxis in order to inform deliberations on,
amongst other things, the overall disease burden posed
by the condition, obtain etiological insights, risk stratifi-
cation and prognosis.
Epidemiological measures of particular interest for
anaphylaxis therefore include measures of incidence and
prevalence, risk factors, and risk of recurrence andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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posed by Last, and adapted for anaphylaxis will be
employed in this review: [10].
Incidence
The number of new cases of anaphylaxis that occur
during a given period in a defined population. Incidence
will be studied as:
 Incidence rate: The number of new cases of
anaphylaxis that occur during a defined period per
unit person-time.
 Cumulative incidence: The number of new cases of
anaphylaxis that occur during a given period per the
population at risk.
Prevalence
The proportion of a defined population known to have
experienced anaphylaxis. Care is required in defining the
appropriate denominator. This epidemiological measure
will be further divided into:
 Point prevalence: the proportion of the population
that has experienced anaphylaxis at a specific time.
 Period prevalence: the proportion of the population
that has experienced anaphylaxis during a given period.
 Lifetime prevalence: the proportion of the population
that at some point in their life will have experienced
anaphylaxis.
Case fatality rate
The proportion of cases of anaphylaxis that proves
fatal (usually defined within a time period). This is also
sometimes known as the case fatality ratio.
Other aspects of interest concern features of persons
who experience anaphylaxis, temporal relationships, and
the factors that lead to its development and recurrence.
The EAACI is in the process of developing the EAACI
Guideline for Food Allergy and Anaphylaxis, and this
systematic review is one of seven inter-linked evidence
syntheses that are being undertaken in order to provide
a state-of-the-art synopsis of the current evidence base
in relation to epidemiology, prevention, diagnosis and
clinical management and impact on quality of life, which
will be used to inform clinical recommendations.
Aims
The aims of this systematic review will be to:
 Understand and describe the epidemiology of
anaphylaxis, i.e. frequency, risk factors and
outcomes of anaphylaxis
 Describe how these characteristics vary by person,
place and time.Methods
Search strategy
A highly sensitive search strategy has been designed to re-
trieve all articles combining the concepts of anaphylaxis
and epidemiology from electronic bibliographic databases.
We have conceptualised the search to incorporate three
elements, as shown in Figure 1: Conceptualisation of
systematic review of the epidemiology of anaphylaxis.
To retrieve systematic reviews, we will use the system-
atic review filter developed at McMaster University Health
Information Research Unit [11]. We have also adapted the
search filter from York University Centre for Reviews and
Dissemination [12] to retrieve incidence, prevalence
and other characteristics describing the epidemiology of
anaphylaxis. Similarly, we also applied the McMaster
filter for prognosis studies [13].




 ISI Web of Science (Thomson Web of Knowledge).
The search strategy has been devised on OVID
MEDLINE and then adapted for the other databases
(see Additional file 1). In all cases the databases will be
searched from 1 January 2000 to 30 September 2012,
and will be limited to Europe based on the definition
provided by the Organization for Economic Co-operation
and Development (OECD) [14]. The countries covered by
this restriction include Austria, Belgium, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Luxembourg, the
Netherlands, Norway, Poland, Portugal, Slovak Republic,
Slovenia, Spain, Sweden, Switzerland, Turkey and the
United Kingdom. All references will be imported into an
EndNote Library and tagged with the name of the data-
base. Searches will be limited to literature from 2000
onwards; because we want to understand and describe
the contemporary epidemiology of anaphylaxis.
Additional references will be located through searching
the references cited by the identified studies, and unpub-
lished work and research in progress will be identified
through discussion with experts in the field. We will invite
experts who are active in the field from a range of disci-
plines and geography to comment on our search strategy,
and the list of included studies.
There will be no language restrictions and, where pos-
sible, all literature will be translated.
Inclusion criteria for study design


























Figure 1 Conceptualisation of systematic review on the epidemiology of anaphylaxis.
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 Case-control studies
 Routine healthcare studies
These study designs were chosen to ensure that the
highest levels of evidence were pooled based on the aims
of this review [15].
Exclusion criteria for study design
 Reviews, discussion papers, non-research letters and
editorials
 Case studies and case series
 Animal studies
Study selection
The titles of the retrieved articles will be checked inde-
pendently by two reviewers according to the above selec-
tion criteria and categorised as: included, not included
and unsure. For those papers in the unsure category we
will retrieve the abstract and re-categorise as above after
further discussion on them. Any discrepancies will be re-
solved by consensus and if necessary a third reviewer will
be consulted to arbitrate. Full text copies of potentially
relevant studies will be obtained and their eligibility for
inclusion independently assessed by two reviewers. Studies
that do not fulfil all of the inclusion criteria will be
excluded.
Risk of bias assessment strategy
Risk of bias assessments will be independently carried
out on each study by two reviewers using the relevant
version of the Critical Appraisal Skills Programme(CASP) quality assessment tool for systematic reviews
[16], cohort studies [17] and case-control studies [18],
which involves an assessment of both internal and exter-
nal validity [19]. Similarly, we will use the Effective Public
Health Practice Project Quality Assessment Tool (EPHPP)
for assessing other forms of quantitative studies such as
cohort analyses, cross-sectional studies and routine
healthcare studies [20]. An overall grading and grading
for the various components of each study (e.g. the
appropriateness of the study design for the research
question, the risk of selection bias, exposure measure-
ment, and outcome assessment) will be given to each
study. Any discrepancies will be resolved by discussion
or, if agreement could not be reached, by arbitration by
a third reviewer.Analysis, data synthesis and reporting
Data will be independently extracted onto a customised
data extraction sheet by two reviewers, and any discrep-
ancies will be resolved by discussion or, if agreement
could not be reached, by arbitration by a third reviewer.
A descriptive summary with data tables will be produced
to summarise the literature. If clinically and statistically
appropriate, meta-analysis using either fixed-effector
random-effects modeling will be undertaken using methods
suggested by Agresti and Coul [21]. A narrative synthesis
of the data will also be undertaken.
This review has been registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
and has registration number CRD42013003702 allocated
to it. The Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) checklist will be used
to guide the reporting of the systematic review [22].
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The occurrence of anaphylaxis can have a profound effect
on the quality of life of the sufferer and their family. The
risk of recurrence may be high and some attacks prove
fatal, sometimes despite immediate, on-site treatment with
epinephrine. Successfully identifying those at greatest
risk of an initial attack, and a recurrence, could reduce
morbidity, but this has proved difficult in practice using
demographic and clinical markers. Secondary analyses
of routine sources of data have proved helpful in
describing the epidemiology of anaphylaxis though the
estimates generated would be considered more reliable
if the data could be validated and linked across primary
and secondary care sectors. Such validation work needs
to be prioritized. This review will aid in providing some
estimates of the frequency of anaphylaxis in Europe. At
present, the best epidemiological estimates appear to
come from North-West Europe, but more information
is needed from Southern and Eastern Europe.
Additional file
Additional file 1: Search strategies.
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